Your browser doesn't support javascript.
loading
FinnGen provides genetic insights from a well-phenotyped isolated population.
Kurki, Mitja I; Karjalainen, Juha; Palta, Priit; Sipilä, Timo P; Kristiansson, Kati; Donner, Kati M; Reeve, Mary P; Laivuori, Hannele; Aavikko, Mervi; Kaunisto, Mari A; Loukola, Anu; Lahtela, Elisa; Mattsson, Hannele; Laiho, Päivi; Della Briotta Parolo, Pietro; Lehisto, Arto A; Kanai, Masahiro; Mars, Nina; Rämö, Joel; Kiiskinen, Tuomo; Heyne, Henrike O; Veerapen, Kumar; Rüeger, Sina; Lemmelä, Susanna; Zhou, Wei; Ruotsalainen, Sanni; Pärn, Kalle; Hiekkalinna, Tero; Koskelainen, Sami; Paajanen, Teemu; Llorens, Vincent; Gracia-Tabuenca, Javier; Siirtola, Harri; Reis, Kadri; Elnahas, Abdelrahman G; Sun, Benjamin; Foley, Christopher N; Aalto-Setälä, Katriina; Alasoo, Kaur; Arvas, Mikko; Auro, Kirsi; Biswas, Shameek; Bizaki-Vallaskangas, Argyro; Carpen, Olli; Chen, Chia-Yen; Dada, Oluwaseun A; Ding, Zhihao; Ehm, Margaret G; Eklund, Kari; Färkkilä, Martti.
Afiliación
  • Kurki MI; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Karjalainen J; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Palta P; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Sipilä TP; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
  • Kristiansson K; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Donner KM; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Reeve MP; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Laivuori H; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
  • Aavikko M; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Kaunisto MA; Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia.
  • Loukola A; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Lahtela E; Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
  • Mattsson H; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Laiho P; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Della Briotta Parolo P; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Lehisto AA; Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Kanai M; Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland.
  • Mars N; Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health, University of Tampere, Tampere, Finland.
  • Rämö J; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Kiiskinen T; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Heyne HO; Helsinki Biobank, University of Helsinki and Hospital District of Helsinki and Uusimaa, Helsinki, Finland.
  • Veerapen K; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Rüeger S; Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
  • Lemmelä S; Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
  • Zhou W; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Ruotsalainen S; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Pärn K; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Hiekkalinna T; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Koskelainen S; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Paajanen T; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
  • Llorens V; Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
  • Gracia-Tabuenca J; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Siirtola H; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Reis K; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Elnahas AG; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Sun B; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Foley CN; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Aalto-Setälä K; Digital Health Center, Hasso Plattner Institute for Digital Engineering, University of Potsdam Potsdam, Potsdam, Germany.
  • Alasoo K; Hasso Plattner Institute for Digital Health at Mount Sinai, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Arvas M; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Auro K; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Biswas S; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Bizaki-Vallaskangas A; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
  • Carpen O; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Chen CY; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
  • Dada OA; Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
  • Ding Z; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Ehm MG; Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Eklund K; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
  • Färkkilä M; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Nature ; 613(7944): 508-518, 2023 01.
Article en En | MEDLINE | ID: mdl-36653562
ABSTRACT
Population isolates such as those in Finland benefit genetic research because deleterious alleles are often concentrated on a small number of low-frequency variants (0.1% ≤ minor allele frequency < 5%). These variants survived the founding bottleneck rather than being distributed over a large number of ultrarare variants. Although this effect is well established in Mendelian genetics, its value in common disease genetics is less explored1,2. FinnGen aims to study the genome and national health register data of 500,000 Finnish individuals. Given the relatively high median age of participants (63 years) and the substantial fraction of hospital-based recruitment, FinnGen is enriched for disease end points. Here we analyse data from 224,737 participants from FinnGen and study 15 diseases that have previously been investigated in large genome-wide association studies (GWASs). We also include meta-analyses of biobank data from Estonia and the United Kingdom. We identified 30 new associations, primarily low-frequency variants, enriched in the Finnish population. A GWAS of 1,932 diseases also identified 2,733 genome-wide significant associations (893 phenome-wide significant (PWS), P < 2.6 × 10-11) at 2,496 (771 PWS) independent loci with 807 (247 PWS) end points. Among these, fine-mapping implicated 148 (73 PWS) coding variants associated with 83 (42 PWS) end points. Moreover, 91 (47 PWS) had an allele frequency of <5% in non-Finnish European individuals, of which 62 (32 PWS) were enriched by more than twofold in Finland. These findings demonstrate the power of bottlenecked populations to find entry points into the biology of common diseases through low-frequency, high impact variants.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenotipo / Enfermedad / Frecuencia de los Genes Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Nature Año: 2023 Tipo del documento: Article País de afiliación: Finlandia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Fenotipo / Enfermedad / Frecuencia de los Genes Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Nature Año: 2023 Tipo del documento: Article País de afiliación: Finlandia